Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Siegfried Holding AG ( (CH:SFZN) ).
Siegfried Holding AG reported profitable growth in the first half of 2025, driven by strong demand for its development and manufacturing services across various markets. Despite challenges such as inflationary pressures and currency fluctuations, the company increased its profitability and confirmed its 2025 outlook, focusing on strategic expansions and technology investments to capture future growth opportunities. Siegfried’s EVOLVE+ strategy is progressing well, with expansions in sterile eye care and spray drying capacities, and new manufacturing lines for pre-filled syringes and cartridges, expected to generate future revenues. The company anticipates continued sales growth and a core EBITDA margin above 22% for 2025.
The most recent analyst rating on (CH:SFZN) stock is a Buy with a CHF102.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.
More about Siegfried Holding AG
The Siegfried Group is a global life sciences company with operations in Switzerland, Germany, Spain, France, Malta, the USA, and China. It specializes in manufacturing pharmaceutical APIs and drug products, including tablets, capsules, sterile vials, ampoules, cartridges, and ointments, and offers development services. The company is publicly listed on the SIX Swiss Exchange.
Average Trading Volume: 55,412
Technical Sentiment Signal: Sell
Current Market Cap: CHF3.96B
Learn more about SFZN stock on TipRanks’ Stock Analysis page.